Gefjon Pharma
Developer of a vaccine platform based on hyper-vesiculating outer membrane vesicles (OMVs) and a genetically modified, high-yield bacterial expression strain. Focuses on a broad‑spectrum E. coli vaccine for poultry with validated proof of concept for both the vaccine and an aerosol delivery method. Engages in collaborative R&D with academic partners and pursues commercialization and grant-funded development.
Industries
Nr. of Employees
small (1-50)
Products
Broad‑spectrum E. coli vaccine for poultry
A vaccine candidate developed from an OMV-based platform intended to protect poultry against multiple E. coli strains; proof of concept demonstrated for vaccine and aerosol delivery.
Broad‑spectrum E. coli vaccine for poultry
A vaccine candidate developed from an OMV-based platform intended to protect poultry against multiple E. coli strains; proof of concept demonstrated for vaccine and aerosol delivery.
Services
Collaborative research partnerships
Joint R&D projects and research collaborations with academic and industry partners to develop platform applications.
Technology licensing and commercialization support
Securing commercialization rights and preparing platform-derived products for market entry through licensing and partner agreements.
Collaborative research partnerships
Joint R&D projects and research collaborations with academic and industry partners to develop platform applications.
Technology licensing and commercialization support
Securing commercialization rights and preparing platform-derived products for market entry through licensing and partner agreements.
Expertise Areas
- Vaccine development (bacterial, veterinary)
- Platform biomanufacturing and process optimization
- Outer membrane vesicle (OMV) technologies
- Aerosol/respiratory vaccine delivery
Key Technologies
- Outer membrane vesicles (OMVs)
- Bacterial strain genetic engineering
- High-yield protein expression systems
- Extraction and downstream processing for biologics